Works by Saito, Haruhiro

Results: 67
    1

    A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.

    Published in:
    Clinical Lung Cancer, 2024, v. 25, n. 3, p. 266, doi. 10.1016/j.cllc.2024.03.003
    By:
    • Garon, Edward B.;
    • Byoung Chul Cho;
    • Luft, Alexander;
    • Alatorre-Alexander, Jorge;
    • Geater, Sarayut Lucien;
    • Dmytro Trukhin;
    • Sang-We Kim;
    • Ursol, Grygorii;
    • Hussein, Maen;
    • Louise Lim, Farah;
    • Cheng-Ta Yang;
    • Araujo, Luiz Henrique;
    • Haruhiro Saito;
    • Reinmuth, Niels;
    • Kohlmann, Milena;
    • Lowery, Caitlin;
    • Mann, Helen;
    • Peters, Solange;
    • Mok, Tony S.;
    • Johnson, Melissa L.
    Publication type:
    Article
    2

    A Phase II Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q).

    Published in:
    Clinical Lung Cancer, 2024, v. 25, n. 1, p. 85, doi. 10.1016/j.cllc.2023.09.006
    By:
    • Shinji Nakamichi;
    • Kaoru Kubota;
    • Kotone Matsuyama;
    • Toshihiro Misumi;
    • Toshiyuki Kozuki;
    • Shunichi Sugawara;
    • Katsuhiko Naoki;
    • Nobuaki Kobayashi;
    • Takehito Shukuya;
    • Tsuneo Shimokawa;
    • Masashi Ishihara;
    • Hiroshi Wakui;
    • Yukio Hosomi;
    • Hiroshi Tanaka;
    • Haruhiro Saito;
    • Shinobu Hosokawa;
    • Yuichi Takiguchi;
    • Takashi Kasai;
    • Hiroshi Nokihara;
    • Ryo Morita
    Publication type:
    Article
    3
    4
    5
    6
    7
    8

    First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.

    Published in:
    Japanese Journal of Clinical Oncology, 2024, v. 54, n. 4, p. 452, doi. 10.1093/jjco/hyad195
    By:
    • Imai, Hisao;
    • Kijima, Takashi;
    • Azuma, Koichi;
    • Kishi, Kazuma;
    • Saito, Haruhiro;
    • Yamaguchi, Teppei;
    • Tanizaki, Junko;
    • Yoneshima, Yasuto;
    • Fujita, Kohei;
    • Watanabe, Satoshi;
    • Kitazono, Satoru;
    • Fukuhara, Tatsuro;
    • Hataji, Osamu;
    • Toi, Yukihiro;
    • Mizutani, Hideaki;
    • Hamakawa, Yusuke;
    • Maemondo, Makoto;
    • Ohsugi, Tomoyuki;
    • Suzuki, Keisuke;
    • Horinouchi, Hidehito
    Publication type:
    Article
    9
    10

    NOTCH1 and CREBBP co‐mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR‐mutated NSCLC: translational research of phase III IMPACT study.

    Published in:
    Molecular Oncology, 2024, v. 18, n. 2, p. 305, doi. 10.1002/1878-0261.13542
    By:
    • Ikeda, Satoshi;
    • Tsuboi, Masahiro;
    • Sakai, Kazuko;
    • Misumi, Toshihiro;
    • Akamatsu, Hiroaki;
    • Shoda, Hiroyasu;
    • Sakakura, Noriaki;
    • Nakamura, Atsushi;
    • Ohde, Yasuhisa;
    • Hayashi, Hidetoshi;
    • Okishio, Kyoichi;
    • Okada, Morihito;
    • Yoshino, Ichiro;
    • Okami, Jiro;
    • Takahashi, Kazuhisa;
    • Ikeda, Norihiko;
    • Tanahashi, Masayuki;
    • Tambo, Yuichi;
    • Saito, Haruhiro;
    • Toyooka, Shinichi
    Publication type:
    Article
    11

    Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors.

    Published in:
    Frontiers in Cell & Developmental Biology, 2024, p. 1, doi. 10.3389/fcell.2023.1324898
    By:
    • Yoshiro Nakahara;
    • Taku Kouro;
    • Satoru Motoyama;
    • Masatomo Miura;
    • Kazuma Fujita;
    • Yuka Igarashi;
    • Naoko Higashijima;
    • Norikazu Matsuo;
    • Hidetomo Himuro;
    • Feifei Wei;
    • Shun Horaguchi;
    • Kayoko Tsuji;
    • Yasunobu Mano;
    • Mitsuru Komahashi;
    • Haruhiro Saito;
    • Koichi Azuma;
    • Tetsuro Sasada
    Publication type:
    Article
    12

    Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors.

    Published in:
    Frontiers in Cell & Developmental Biology, 2024, p. 1, doi. 10.3389/fcell.2023.1324898
    By:
    • Yoshiro Nakahara;
    • Taku Kouro;
    • Satoru Motoyama;
    • Masatomo Miura;
    • Kazuma Fujita;
    • Yuka Igarashi;
    • Naoko Higashijima;
    • Norikazu Matsuo;
    • Hidetomo Himuro;
    • Feifei Wei;
    • Shun Horaguchi;
    • Kayoko Tsuji;
    • Yasunobu Mano;
    • Mitsuru Komahashi;
    • Haruhiro Saito;
    • Koichi Azuma;
    • Tetsuro Sasada
    Publication type:
    Article
    13

    Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors.

    Published in:
    Frontiers in Cell & Developmental Biology, 2024, p. 1, doi. 10.3389/fcell.2023.1324898
    By:
    • Yoshiro Nakahara;
    • Taku Kouro;
    • Satoru Motoyama;
    • Masatomo Miura;
    • Kazuma Fujita;
    • Yuka Igarashi;
    • Naoko Higashijima;
    • Norikazu Matsuo;
    • Hidetomo Himuro;
    • Feifei Wei;
    • Shun Horaguchi;
    • Kayoko Tsuji;
    • Yasunobu Mano;
    • Mitsuru Komahashi;
    • Haruhiro Saito;
    • Koichi Azuma;
    • Tetsuro Sasada
    Publication type:
    Article
    14

    Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.

    Published in:
    Biomedicines, 2024, v. 12, n. 8, p. 1831, doi. 10.3390/biomedicines12081831
    By:
    • Horaguchi, Shun;
    • Nakahara, Yoshiro;
    • Igarashi, Yuka;
    • Kouro, Taku;
    • Wei, Feifei;
    • Murotani, Kenta;
    • Udagawa, Seiichi;
    • Higashijima, Naoko;
    • Matsuo, Norikazu;
    • Murakami, Shuji;
    • Kato, Terufumi;
    • Kondo, Tetsuro;
    • Xiang, Huihui;
    • Kasajima, Rika;
    • Himuro, Hidetomo;
    • Tsuji, Kayoko;
    • Mano, Yasunobu;
    • Komahashi, Mitsuru;
    • Miyagi, Yohei;
    • Saito, Haruhiro
    Publication type:
    Article
    15
    16
    17
    18

    A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non‐small cell lung cancer (LOGIK1902).

    Published in:
    Thoracic Cancer, 2024, v. 15, n. 29, p. 2128, doi. 10.1111/1759-7714.15444
    By:
    • Harada, Taishi;
    • Sasaki, Tomonari;
    • Ishii, Hidenobu;
    • Takemoto, Shinnosuke;
    • Hisamatsu, Yasushi;
    • Saito, Haruhiro;
    • Yoneshima, Yasuto;
    • Komiya, Kazutoshi;
    • Kashiwabara, Kosuke;
    • Naoki, Katsuhiko;
    • Ogawa, Tomohiro;
    • Takeoka, Hiroaki;
    • Saruwatari, Koichi;
    • Ito, Kensaku;
    • Tsuchiya‐Kawano, Yuko;
    • Mizuno, Keiko;
    • Shimose, Takayuki;
    • Shioyama, Yoshiyuki;
    • Okamoto, Isamu
    Publication type:
    Article
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37

    Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M–positive non–small cell lung cancer: West Japan Oncology Group 8815L/LPS study.

    Published in:
    Cancer (0008543X), 2020, v. 126, n. 9, p. 1940, doi. 10.1002/cncr.32749
    By:
    • Takahama, Takayuki;
    • Azuma, Koichi;
    • Shimokawa, Mototsugu;
    • Takeda, Masayuki;
    • Ishii, Hidenobu;
    • Kato, Terufumi;
    • Saito, Haruhiro;
    • Daga, Haruko;
    • Tsuboguchi, Yuko;
    • Okamoto, Isamu;
    • Otsubo, Kohei;
    • Akamatsu, Hiroaki;
    • Teraoka, Shunsuke;
    • Takahashi, Toshiaki;
    • Ono, Akira;
    • Ohira, Tatsuo;
    • Yokoyama, Toshihide;
    • Sakai, Kazuko;
    • Yamamoto, Nobuyuki;
    • Nishio, Kazuto
    Publication type:
    Article
    38

    Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.

    Published in:
    2020
    By:
    • Takahama, Takayuki;
    • Azuma, Koichi;
    • Shimokawa, Mototsugu;
    • Takeda, Masayuki;
    • Ishii, Hidenobu;
    • Kato, Terufumi;
    • Saito, Haruhiro;
    • Daga, Haruko;
    • Tsuboguchi, Yuko;
    • Okamoto, Isamu;
    • Otsubo, Kohei;
    • Akamatsu, Hiroaki;
    • Teraoka, Shunsuke;
    • Takahashi, Toshiaki;
    • Ono, Akira;
    • Ohira, Tatsuo;
    • Yokoyama, Toshihide;
    • Sakai, Kazuko;
    • Yamamoto, Nobuyuki;
    • Nishio, Kazuto
    Publication type:
    journal article
    39

    Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.

    Published in:
    2016
    By:
    • Takeda, Masayuki;
    • Yamanaka, Takeharu;
    • Seto, Takashi;
    • Hayashi, Hidetoshi;
    • Azuma, Koichi;
    • Okada, Morihito;
    • Sugawara, Shunichi;
    • Daga, Haruko;
    • Hirashima, Tomonori;
    • Yonesaka, Kimio;
    • Urata, Yoshiko;
    • Murakami, Haruyasu;
    • Saito, Haruhiro;
    • Kubo, Akihito;
    • Sawa, Toshiyuki;
    • Miyahara, Eiji;
    • Nogami, Naoyuki;
    • Nakagawa, Kazuhiko;
    • Nakanishi, Yoichi;
    • Okamoto, Isamu
    Publication type:
    journal article
    40
    41
    42
    43
    44
    45

    Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer.

    Published in:
    Cancer Medicine, 2021, v. 10, n. 2, p. 626, doi. 10.1002/cam4.3641
    By:
    • Shimokawa, Tsuneo;
    • Yamada, Kazuhiko;
    • Tanaka, Hiroshi;
    • Kubota, Kaoru;
    • Takiguchi, Yuichi;
    • Kishi, Kazuma;
    • Saito, Haruhiro;
    • Hosomi, Yukio;
    • Kato, Terufumi;
    • Harada, Daijiro;
    • Otani, Sakiko;
    • Kasai, Takashi;
    • Nakamura, Yoichi;
    • Misumi, Toshihiro;
    • Yamanaka, Takeharu;
    • Okamoto, Hiroaki
    Publication type:
    Article
    46

    Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.

    Published in:
    Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-025-58186-7
    By:
    • Tanaka, Kentaro;
    • Sugisaka, Jun;
    • Shiraishi, Yoshimasa;
    • Watanabe, Yasutaka;
    • Daga, Haruko;
    • Azuma, Koichi;
    • Nishino, Kazumi;
    • Mori, Masahide;
    • Ota, Takayo;
    • Saito, Haruhiro;
    • Hata, Akito;
    • Sakaguchi, Tadashi;
    • Kozuki, Toshiyuki;
    • Akamatsu, Hiroaki;
    • Matsumoto, Hirotaka;
    • Tachihara, Motoko;
    • Wakuda, Kazushige;
    • Sato, Yuki;
    • Ozaki, Tomohiro;
    • Tsuchiya-Kawano, Yuko
    Publication type:
    Article
    47
    48
    49
    50

    Multi-omics analysis-based clinical and functional significance of a novel prognostic and immunotherapeutic gene signature derived from amino acid metabolism pathways in lung adenocarcinoma.

    Published in:
    Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1361992
    By:
    • Xiang, Huihui;
    • Kasajima, Rika;
    • Azuma, Koichi;
    • Tagami, Tomoyuki;
    • Hagiwara, Asami;
    • Nakahara, Yoshiro;
    • Saito, Haruhiro;
    • Igarashi, Yuka;
    • Wei, Feifei;
    • Ban, Tatsuma;
    • Yoshihara, Mitsuyo;
    • Nakamura, Yoshiyasu;
    • Sato, Shinya;
    • Koizume, Shiro;
    • Tamura, Tomohiko;
    • Sasada, Tetsuro;
    • Miyagi, Yohei
    Publication type:
    Article